Here's Why This Dividend King Is a Buy for Income Investors

During a market correction, sometimes even the highest quality blue-chip stocks can be hit hard. With its stock falling 23% so far this year, Abbott Laboratories (NYSE: ABT) is a fitting recent example. Compared to the S&P 500 index's 20% year-to-date decline, Abbott Laboratories' drop has been a little more pronounced.

But this sell-off appears to have created a buying opportunity for yield-hungry investors. Let's dive into Abbott Laboratories' fundamentals and valuation to find out why.

Image source: Getty Images.

Continue reading

Source Fool.com